JP2023519501A5 - - Google Patents

Info

Publication number
JP2023519501A5
JP2023519501A5 JP2022552307A JP2022552307A JP2023519501A5 JP 2023519501 A5 JP2023519501 A5 JP 2023519501A5 JP 2022552307 A JP2022552307 A JP 2022552307A JP 2022552307 A JP2022552307 A JP 2022552307A JP 2023519501 A5 JP2023519501 A5 JP 2023519501A5
Authority
JP
Japan
Prior art keywords
oligomer compound
pharmaceutical composition
weeks
composition according
once
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022552307A
Other languages
English (en)
Japanese (ja)
Other versions
JP7795467B2 (ja
JP2023519501A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/022069 external-priority patent/WO2021183857A1/en
Publication of JP2023519501A publication Critical patent/JP2023519501A/ja
Publication of JP2023519501A5 publication Critical patent/JP2023519501A5/ja
Priority to JP2025266910A priority Critical patent/JP2026048915A/ja
Application granted granted Critical
Publication of JP7795467B2 publication Critical patent/JP7795467B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022552307A 2020-03-13 2021-03-12 プレカリクレイン関連の状態を治療及び予防するための組成物及び方法 Active JP7795467B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025266910A JP2026048915A (ja) 2020-03-13 2025-12-19 プレカリクレイン関連の状態を治療及び予防するための組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062989427P 2020-03-13 2020-03-13
US62/989,427 2020-03-13
PCT/US2021/022069 WO2021183857A1 (en) 2020-03-13 2021-03-12 Compositions and methods for treating and preventing prekallikrein-associated conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025266910A Division JP2026048915A (ja) 2020-03-13 2025-12-19 プレカリクレイン関連の状態を治療及び予防するための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2023519501A JP2023519501A (ja) 2023-05-11
JP2023519501A5 true JP2023519501A5 (https=) 2024-03-26
JP7795467B2 JP7795467B2 (ja) 2026-01-07

Family

ID=77672313

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022552307A Active JP7795467B2 (ja) 2020-03-13 2021-03-12 プレカリクレイン関連の状態を治療及び予防するための組成物及び方法
JP2025266910A Pending JP2026048915A (ja) 2020-03-13 2025-12-19 プレカリクレイン関連の状態を治療及び予防するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025266910A Pending JP2026048915A (ja) 2020-03-13 2025-12-19 プレカリクレイン関連の状態を治療及び予防するための組成物及び方法

Country Status (9)

Country Link
US (1) US20230149438A1 (https=)
EP (1) EP4118208A4 (https=)
JP (2) JP7795467B2 (https=)
KR (1) KR20220152569A (https=)
CN (1) CN115244179A (https=)
BR (1) BR112022016167A2 (https=)
IL (1) IL295631A (https=)
MX (1) MX2022011205A (https=)
WO (1) WO2021183857A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102365486B1 (ko) 2013-08-28 2022-02-18 아이오니스 파마수티컬즈, 인코포레이티드 프리칼리크레인 (pkk) 발현의 조절

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102365486B1 (ko) * 2013-08-28 2022-02-18 아이오니스 파마수티컬즈, 인코포레이티드 프리칼리크레인 (pkk) 발현의 조절
HUE052709T2 (hu) * 2014-05-01 2021-05-28 Ionis Pharmaceuticals Inc Módosított antiszensz oligonukleotidok konjugátumai és azok alkalmazása PKK expressziójának módosítására
ES2982752T3 (es) * 2015-10-22 2024-10-17 Iltoo Pharma Composiciones farmacéuticas de il-2
PL4119569T3 (pl) * 2015-11-06 2024-11-18 Ionis Pharmaceuticals, Inc. Sprzężone związki antysensowne do zastosowania w terapii
TW201828952A (zh) * 2017-02-08 2018-08-16 美商Ionis製藥公司 調節血管舒緩素b1(klkb1)用於治療頭痛

Similar Documents

Publication Publication Date Title
JP2013533858A5 (https=)
CN105311029A (zh) 抗肿瘤活性的喹啉衍生物
Maspero et al. Long-term safety of dupilumab in patients with moderate-to-severe asthma: TRAVERSE continuation study
JP2022533981A5 (https=)
CN112638378A (zh) 用于根除幽门螺杆菌的组合物
JP7639156B2 (ja) チルゼパチド治療方法
JP2024524984A (ja) 閉塞性睡眠時無呼吸を治療する方法
KR20230038644A (ko) 코로나바이러스 치료를 위한 피르페니돈
JP2023519501A5 (https=)
TW202444371A (zh) 嚴重發熱伴血小板減少症候群病毒感染症之治療劑
Harfouch et al. Therapeutic approaches for COVID 19: Challenges and successes
JP2017508737A5 (https=)
US20250332136A1 (en) Composition and methods for treatment or prophylaxis of coronavirus and cancers
US8198293B2 (en) Oxymatrine compositions and related methods for treating and preventing chronic infectious diseases
CN114272254B (zh) 甘草次酸和芍药苷的组合在治疗肝损伤、肝纤维化中的应用
JP2024506041A (ja) 潰瘍性大腸炎を予防、処置、または改善するためのアミセリモド
JP2025522146A5 (https=)
US20230270724A1 (en) PDE3 inhibitors for treating viral infections
US6194460B1 (en) Composition for treating cough induced by angiotensin converting enzyme inhibitors
CN115969828B (zh) 替拉曲可在制备预防和/或治疗黄热病毒感染的药物中的应用
EP2307018B1 (en) Oxymatrine compositions and use thereof for treating and preventing chronic infectious diseases
CN117503763A (zh) 巴马汀在治疗高血压中的应用
HK40094222A (zh) 预防、治疗或改善溃疡性结肠炎的阿米莫德
TW200824697A (en) Use of ATP in controlled regional reperfusion as treatment during acute myocardial infarction
CN114569618A (zh) 一种头孢克洛的复方制剂及制备方法